Shares of PerkinElmer, Inc. (NYSE:PKI) have received a consensus recommendation of “Hold” from the sixteen analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $67.17.

A number of analysts have weighed in on PKI shares. Evercore ISI reissued an “in-line” rating and issued a $68.00 price target (up from $62.50) on shares of PerkinElmer in a report on Thursday, June 22nd. BidaskClub downgraded shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Barclays PLC set a $55.00 price target on shares of PerkinElmer and gave the company a “sell” rating in a report on Saturday, May 6th. Cantor Fitzgerald reissued a “hold” rating and issued a $65.00 price target on shares of PerkinElmer in a report on Friday, May 5th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $81.00 price objective on shares of PerkinElmer in a research note on Friday, August 4th.

TRADEMARK VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/19/perkinelmer-inc-pki-given-consensus-rating-of-hold-by-brokerages.html.

In related news, insider Andrew Okun sold 4,358 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $65.00, for a total transaction of $283,270.00. Following the completion of the sale, the insider now owns 16,799 shares in the company, valued at approximately $1,091,935. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Peter Barrett sold 10,000 shares of the stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $63.22, for a total transaction of $632,200.00. Following the sale, the director now owns 29,200 shares of the company’s stock, valued at approximately $1,846,024. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Large investors have recently made changes to their positions in the company. Toronto Dominion Bank boosted its stake in shares of PerkinElmer by 26.4% in the second quarter. Toronto Dominion Bank now owns 35,925 shares of the medical research company’s stock worth $2,447,000 after buying an additional 7,505 shares during the period. WINTON GROUP Ltd boosted its stake in shares of PerkinElmer by 89.6% in the second quarter. WINTON GROUP Ltd now owns 238,331 shares of the medical research company’s stock worth $16,240,000 after buying an additional 112,611 shares during the period. Koch Industries Inc. purchased a new stake in shares of PerkinElmer during the second quarter worth about $364,000. Piedmont Investment Advisors LLC boosted its stake in shares of PerkinElmer by 42.6% in the second quarter. Piedmont Investment Advisors LLC now owns 22,944 shares of the medical research company’s stock worth $1,563,000 after buying an additional 6,858 shares during the period. Finally, Castleark Management LLC boosted its stake in shares of PerkinElmer by 22.9% in the second quarter. Castleark Management LLC now owns 68,915 shares of the medical research company’s stock worth $4,696,000 after buying an additional 12,855 shares during the period. Institutional investors and hedge funds own 91.47% of the company’s stock.

PerkinElmer (NYSE:PKI) opened at 63.47 on Friday. The company’s 50 day moving average is $66.79 and its 200 day moving average is $61.18. PerkinElmer has a 12-month low of $45.35 and a 12-month high of $70.16. The firm has a market cap of $7.00 billion, a price-to-earnings ratio of 19.14 and a beta of 0.75.

PerkinElmer (NYSE:PKI) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The firm had revenue of $547 million during the quarter, compared to the consensus estimate of $554.14 million. During the same period in the prior year, the firm earned $0.67 EPS. The business’s revenue was up 2.0% on a year-over-year basis. On average, equities analysts anticipate that PerkinElmer will post $2.89 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 10th. Investors of record on Friday, October 20th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Thursday, October 19th. PerkinElmer’s dividend payout ratio (DPR) is currently 8.46%.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.